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Abstract
Background/Objectives People with metabolically healthy obesity (MHO) may still have an increased risk for cardiovas-
cular mortality compared to metabolically healthy lean (MHL) individuals. However, the mechanisms linking obesity to
cardiovascular diseases are not entirely understood. We therefore tested the hypothesis that circulating cell adhesion
molecules (CAMs) are higher in MHO compared to MHL individuals.
Subjects/Methods Serum concentrations of soluble intercellular adhesion molecule-1 (sICAM-1), soluble vascular adhesion
molecule-1 (sVCAM-1), E-selectin and P-selectin were measured in age- and sex-matched groups of MHL (n= 32), MHO
categorized into BMI-matched insulin sensitive (IS, n= 32) or insulin resistant (IR) obesity (n= 32) and people with
metabolically unhealthy obesity (MUO, n= 32).
Results Indeed, individuals with MHO have significantly higher sICAM-1, E-selectin, and P-selectin serum concentrations
compared to MHL people. However, these CAMs are still significantly lower in IS compared to IR MHO. There was no
difference between the groups in sVCAM-1 serum concentrations. Compared to all other groups, circulating adhesion
molecules were significantly higher in individuals with MUO.
Conclusions These findings suggest that obesity-related increased cardiovascular risk is reflected and may be mediated by
significantly higher CAMs. The mechanisms causing elevated adhesion molecules even in the absence of overt cardio-
metabolic risk factors and whether circulating CAMs could predict cardiovascular events need to be explored.
Introduction
The concept of metabolically healthy obesity (MHO) derived
from clinical observations that a subgroup of people with
obesity does not exhibit cardio-metabolic abnormalities [1]. The
well documented premature atherosclerosis in people with
obesity [2] could be mediated by metabolic (impaired glucose
and lipid metabolism), cardiovascular (hypertension, circulating
atherogenic factors) or pro-inflammatory abnormalities [1].
Indeed, individuals with MHO have a lower risk to develop
cardiovascular diseases (CVDs) compared to people with
metabolically unhealthy obesity (MUO) [3, 4]. However, MHO
does not seem to represent a benign condition, because people
with MHO still have an increased risk for coronary heart dis-
ease, cerebrovascular disease, and heart failure compared to
metabolically healthy lean (MHL) individuals [4]. Beyond the
effects of smoking, elevated LDL-cholesterol, physical activity
and fitness, there seem to be obesity-related factors linking fat
accumulation or alterations in fat distribution to a higher cardio-
metabolic risk even in people with MHO [1, 3].
Factors secreted from adipose tissue may mechanistically
link increased fat mass in obesity to endothelial dysfunction
These authors contributed equally: Arij Mulhem, Yusef Moulla
* Matthias Blüher
bluma@medizin.uni-leipzig.de
1 Medical Department III – Endocrinology, Nephrology,
Rheumatology, University of Leipzig Medical Center,
Leipzig, Germany
2 Clinic for Visceral, Transplantation and Thorax and Vascular
Surgery, University Hospital Leipzig, Leipzig, Germany
3 Helmholtz Institute for Metabolic, Obesity and Vascular Research
(HI-MAG) of the Helmholtz Zentrum München at the University
of Leipzig, Leipzig, Germany
4 Division of Renal Medicine, Department of Clinical Science,
Intervention and Technology, Karolinska Institutet,
Stockholm, Sweden
5 Institute of Nutritional Science, Justus-Liebig-University,
Giessen, Germany
6 Clinic of Visceral Surgery, Städtisches Klinikum Karlsruhe,
Karlsruhe, Germany
7 Institute of Laboratory Medicine, Clinical Chemistry and
















and atherosclerotic cardiovascular disease (ASCVD) [5]. In
this context, we have shown that MHO is associated with
higher adiponectin and lower C-reactive protein (CRP), pro-
granulin, chemerin, fetuin-A, retinol binding protein-4,
dipeptidyl peptidase-4 serum concentrations compared to
MUO [1, 6]. Among the factors linking obesity to ASCVD,
cell adhesion molecules (CAMs) such as endothelial leuko-
cyte adhesion molecule-1 (E-selectin or cluster of differ-
entiation (CD) 62E), platelet (P)-selectin (CD62P),
intercellular cell adhesion molecule-1 (ICAM-1; CD54), and
vascular cell adhesion molecule-1 (VCAM-1, CD106) may
play a mechanistic role. CAMs have been shown to be
independently of glucose metabolism parameters associated
with obesity [7]. CAMs are glycoproteins expressed on the
surface of various cells in response to signals of inflammation
and mediate binding with the extracellular matrix [8, 9]. They
are involved in migration of leukocytes to inflammatory sites
[8]. For example, E-selectin mediates the first adhesion step of
monocytes to the vascular wall whereas ICAM-1 and VCAM-
1 both mediate adhesion to endothelial cells and transmigra-
tion of leukocytes into the subendothelial space [8, 9].
P-selectin mediates the interaction of endothelial cells or
platelets with leukocytes [8]. After proteolytic cleavage, the
extracellular domain of CAMs is released into the circulation
and soluble CAMs (sCAMs) correlate with their cellular
surface expression [8]. Serum concentrations of sCAMs are
associated with parameters of glycemic control in individuals
with type 2 diabetes and prediabetes [10]. Importantly,
increased CAMs production particularly in visceral adipose
tissue may directly link adiposity to increased ASCVD risk in
obesity [11]. We therefore tested the hypothesis that serum
CAMs concentrations discriminate age- and sex-matched
MHL from MHO either defined as insulin sensitive (IS) or
insulin resistant (IR) by euglycemic-hyperinsulinemic clamps.
Methods
Subjects
For the purpose of this study, we selected 128 individuals
from the Leipzig Obesity Biobank to define age- and sex-
matched groups of IS metabolically healthy lean (MHL,
n= 32), IS (n= 32), IR MHO (n= 32) and MUO (n= 32).
IS and IR MHO as well as MUO subgroups were matched for
BMI and body fat mass (Table 1). Definition of the MHO
subgroups was based on the glucose infusion rate (GIR)
during the last 30min of the steady state in euglycemic-
hyperinsulinemic clamps (IS: GIR > 70 μmol/kg/min; IR:
GIR < 60 μmol/kg/min) as described [6]. All individuals ful-
filled the following inclusion criteria: (1) men or pre-
menopausal women, (2) age >18years, (3) fasting plasma
glucose <7.0mmol/l; (4) HbA1c < 6.0%, (5) stable body
weight, defined as the absence of fluctuations of >3% of body
weight for ≥3 months before blood tests. In addition, the
following exclusion criteria have been defined: (1) medical
and family history of type 1 or type 2 diabetes; (2) medical
history of hypertension or systolic blood pressure >140mmHg
and diastolic blood pressure >85mmHg (except for the MUO
group); (3) estimated glomerular filtration rate <90ml/min, (4)
any acute or chronic inflammatory disease or symptoms of
infection; (5) clinical evidence of either cardiovascular or
peripheral artery disease; (6) smoking; (7) LDL-cholesterol
>4mmol/l; (8) any type of malignant disease; (9) thyroid
dysfunction; (10) Cushing’s disease or hypercortisolism; (11)
alcohol or drug abuse; (12) pregnancy; (13) concomitant
medication, except contraceptives. We used the criteria pro-
posed by the Healthy Obese Project to define MHO [12]. BMI
was calculated as weight divided by squared height. Waist
circumference was measured at the midpoint between the
lower ribs and iliac crest. Percentage body fat was measured
by bioimpedance analysis. Abdominal visceral and sub-
cutaneous fat areas were calculated using computed tomo-
graphy or MRI scans at the level of L4–L5. Insulin sensitivity
was assessed using the euglycemic-hyperinsulinemic clamp
method as described [6]. The study was approved by Ethics
committee of the University of Leipzig (approval numbers:
159-12-21052012 and 017-12-23012012) and all subjects
gave written informed consent before taking part in the study.
Analyses of cell adhesion molecules and other
serum parameters
All baseline blood samples were collected between 8 and 10
am after an overnight fast. Serum concentrations of sICAM-1,
sVCAM-1, sE-selectin, and sP-selectin were measured by
monoclonal antibody-based ELISAs (product numbers
DCD540, DVC00, DSLE00, BBE6; R&D Systems, Abing-
ton, UK). Plasma insulin was measured with an enzyme
immunometric assay for the IMMULITE automated analyzer
(Diagnostic Products Corporation, Los Angeles, CA). Serum
high-sensitive CRP, adiponectin, interleukin (IL)-6, and leptin
were measured as previously described [6].
Statistical analyses
Data are shown as means ± SD. Statistical analysis was
performed using SPSS version 12.0 (Chicago, IL). Group
differences were analyzed using Student’s tests. P values <
0.05 were considered statistically significant.
Results
Study participants fulfilling strict criteria of cardio-metabolic
health [12] have been selected from a larger biobank
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(n > 5000 donors) to compare serum CAMs concentrations
between people with a BMI < 25 kg/m² (MHL) and a BMI ≥
35 kg/m² (MHO), which do not exhibit main cardio-metabolic
risk factors including smoking, high LDL-cholesterol,
hyperglycemia, dyslipidemia, hypertension, or any evidence
for CVD (Table 1). Study groups were matched for age
and sex, but showed differences in parameters of anthro-
pometry, fat distribution, insulin sensitivity, glucose, and lipid
metabolism and for the adipokines adiponectin and leptin
(Table 1). All subgroups included some individuals with
impaired fasting glucose (IFG) (6.1–6.9 mmol/l), but without
an imbalanced distribution between the groups (Table 1). To
test the potential influence of impaired insulin sensitivity, the
MHO group was further categorized into BMI- and body fat
mass matched subgroups of IS and IR obesity as described
[6]. Compared to the IR MHO subgroup, the MUO subgroup
was characterized by significantly higher blood pressure,
higher fasting triglyceride, and lower HDL-cholesterol serum
concentrations (Table 1). Patients with diabetes were not
included into the MUO group.
Circulating CAMs concentrations were not different between
women and men. We found that sICAM-1, sE-selectin, and
Table 1 Characteristics of the study participants.
Study group Metabolically
healthy lean






N (Womenmen) 32 (23/9) 32 (23/9) 32 (23/9) 32 (23/9)
Age (years) 43.7 ± 7.2 42.7 ± 9.4 42.8 ± 6.7 42.7 ± 4.2
Body weight (kg) 66 ± 7 135 ± 21** 130 ± 17** 133 ± 12**
BMI (kg/m²) 23.4 ± 1.5 45.9 ± 6.8** 45.3 ± 4.7** 45.5 ± 3.4**
Body fat (%) 22.6 ± 4.8 44.7 ± 5.6** 45.1 ± 5.4** 44.9 ± 6.1**
Visceral fat area (cm²) 85 ± 86 133 ± 24** 320 ± 78**,## 411 ± 119**,##,§
Subcutaneous fat area (cm²) 119 ± 211 932 ± 124** 926 ± 131** 909 ± 158**
Waist circumference (cm) 84 ± 17 142 ± 13** 139 ± 11** 140 ± 9**
Systolic blood pressure (mmHg) 117 ± 8 121 ± 7 124 ± 4 144 ± 18**, ##,§§
Diastolic blood pressure (mmHg) 76 ± 6 74 ± 5 74 ± 4 92 ± 11**, ##,§§
FPG (mmol/l) 5.6 ± 0.6 5.4 ± 0.3 5.7 ± 0.3## 5.6 ± 0.5
Impaired fasting glucose (n) 4 2 3 4
FPI (pmol/l) 17.6 ± 19.4 28.7 ± 14.1** 106.4 ± 27.1**,## 129.9 ± 37.3**,##
HbA1c (%) 5.39 ± 0.4 5.33 ± 0.2 5.56 ± 0.3## 5.46 ± 0.3
Clamp GIR (μmol/kg/min) 89.5 ± 30 89.3 ± 9.1 29 ± 11**,## 35 ± 16**,##
Cholesterol (mmol/l) 5.44 ± 0.82 4.84 ± 0.9* 5.11 ± 1.06 5.32 ± 0.94
HDL-Cholesterol (mmol/l) 1.40 ± 0.35 1.39 ± 0.39 1.01 ± 0.27*,## 0.83 ± 0.13*, ##,§
LDL-Cholesterol (mmol/l) 3.24 ± 0.96 2.96 ± 0.88 3.09 ± 0.82 2.85 ± 0.73
Triglycerides (mmol/l) 1.42 ± 0.84 1.23 ± 0.47 1.99 ± 1.18## 2.41 ± 1.3##,§
Free fatty acids (mmol/l) 0.22 ± 0.21 0.22 ± 0.15 0.49 ± 0.19**,## 0.55 ± 0.27**,##
hsCRP (mg/l) 2.62 ± 2.79 2.61 ± 2.24 3.65 ± 1.48## 3.92 ± 0.94##
IL-6 (pg/ml) 0.89 ± 1.16 1.31 ± 1.63 2.18 ± 1.69* 2.49 ± 1.05*,#
Leukocytes (Gpt/l) 7.8 ± 4.8 7.3 ± 2.4 8.3 ± 4.5 7.9 ± 2.8
ALAT (μkat/l) 0.45 ± 0.17 0.44 ± 0.16 0.51 ± 0.15** 0.54 ± 0.19**
ASAT (μkat/l) 0.39 ± 0.17 0.43 ± 0.14 0.55 ± 0.16# 0.59 ± 0.21#
GGT (μkat/l) 0.47 ± 0.20 0.44 ± 0.20 0.58 ± 0.22*,# 0.53 ± 0.16*,#
Adiponectin (μg/ml) 12.1 ± 7.2 6.9 ± 3.4* 3.1 ± 1.5**,## 2.7 ± 1.9**,##
Leptin (pg/ml) 12 ± 12 41 ± 13** 43 ± 12** 41 ± 9**
Data are means ± SD.
ALAT Alanine-Aminotransferase, ASAT Aspartate-Aminotransferase, BMI body mass index, FPG fasting plasma glucose, FPI fasting plasma
insulin, GGT Gamma-Glutamyl Transpeptidase, HbA1c glycated hemoglobin, HDL high density lipoprotein, hsCRP high sensitivity C-reactive
protein, IL-6 Interleukin 6, LDL low density lipoprotein.
*p < 0.05; **p < 0.01 for comparisons to metabolically healthy lean control group. #p < 0.05; ##p < 0.01 compared to metabolically healthy obesity
group. §p < 0.05; §§p < 0.01 for comparisons between MUO and IR MHO subgroups.
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sP-selectin serum concentrations are significantly higher in
individuals with MHO compared to MHL with additional sig-
nificant group differences between IS and IR MHO (Fig. 1).
The significant differences in circulating CAMs remained sig-
nificant even after adjusting to main cardio-metabolic risk
parameters (blood pressure, LDL-cholesterol, fasting plasma
glucose, HbA1c). In contrast, sVCAM-1 concentrations were
indistinguishable between the three subgroups (Fig. 1). Serum
concentrations of the four adhesion molecules were significantly
higher in the MUO subgroup compared to the other subgroups
(Fig. 1). We omitted further correlation analyses across the
entire cohort to avoid the bias introduced with our group
selection criteria.
Discussion
The key finding of our study is that people with MHO have
significantly higher serum concentrations of the CAMs
ICAM-1, E-selectin, and P-selectin compared to age- and
sex-matched healthy lean individuals. In addition, we
identified impaired insulin sensitivity as an additional factor
contributing to significantly higher circulating CAMs even
within the group of MHO. This observation extends our
previous findings that people with IR MHO are character-
ized by an atherogenic and diabetogenic serum parameter
profile that includes lower adiponectin, higher CRP, pro-
granulin, chemerin, fetuin-A, and others compared to people
with IS MHO [6]. Higher blood pressure and fasting tri-
glycerides together with lower HDL-cholesterol in the group
of MUO is associated with significantly higher circulating
adhesion molecules compared to all other groups.
It has been debated whether MHO represents a benign
subphenotype of obesity, which may be protected against
ASCVD, type 2 diabetes, and other cardio-metabolic dis-
eases [1, 13]. Moreover, individuals with MHO may not
benefit from weight loss with regard to their obesity-related
cardiovascular and metabolic risk [1, 13]. The concept that
MHO is protected against cardio-metabolic diseases has
been recently challenged by retrospective analyses of The
Health Improvement Network (THIN) database [4]. In this
study of 3.5 million men and women from the United
A                                                                       B
C                                    D
Fig. 1 Serum concentrations of soluble ICAM-1, VCAM-1, E-
selectin and P-selectin. Comparison between age- and sex-matched
groups of metabolically healthy lean (MHL) individuals (BMI ≤ 25 kg/
m², n= 32), patients with metabolically unhealthy obesity (MUO;
BMI ≥ 35 kg/m², n= 32), and people with metabolically healthy obe-
sity (MHO; BMI ≥ 35 kg/m²) divided into age-, sex-, and BMI-
matched groups of insulin sensitive (IS, n= 32) or insulin resistant
(IR, n= 32) MHO. MHO and MUO were defined by recently reported
criteria [12]. Distinction between IS and IR obesity is based on the
glucose infusion rate (GIR) in euglycemic-hyperinsulinemic clamp
(IS: GIR > 70 μmol/kg/min; IR: GIR < 60 μmol/kg/min) as described in
detail previously [6]. a sICAM-1, (b) sVCAM-1, (c) sE-selectin, and
(d) sP-selectin serum concentrations in the three different groups. *p <
0.05; **p < 0.01; ***p < 0.001. sICAM-1 soluble intercellular adhe-
sion molecule-1, sVCAM-1 soluble vascular cell adhesion molecule-1.
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Kingdom, CVD events (adjusted for age, BMI, sex, self-
reported smoking, and social deprivation) were more fre-
quently found in patients with obesity compared to lean
individuals even without overt metabolic abnormalities [4].
It can be argued that higher CVD event risk may result from
not systematically studied residual confounding factors such
as dietary, behavior, or physical activity factors. In addition,
standardized criteria for the definition of MHO are impor-
tant to translate database findings into potential mechanisms
linking obesity to cardio-metabolic disease risk. We there-
fore tested the hypothesis that circulating CAMs are higher
in MHO compared to MHL in a defined human model
system of age- and sex-matched groups fulfilling the
recently proposed strict diagnostic criteria for metabolic
health [12]. Increased CAMs serum concentrations in MHO
compared to MHL individuals suggest that higher adipose
tissue mass, a known source of increased CAMs production
[11], explains the observed differences. However, higher fat
mass in MHO compared to MHL did not translate into
differences in circulating VCAM-1 in our study. We pos-
tulate that the contrasting data for VCAM-1 compared to
the other tested CAMs could be caused by specific reg-
ulatory factors including adipokines like chemerin. Indeed,
chemerin serum concentrations significantly discriminate IS
and IR obesity [4]. In this context, it has been shown that
chemerin induces ICAM-1 and E-selectin expression in
endothelial cells, but not VCAM-1 in vitro [14]. In contrast
to sVCAM-1, higher chemerin serum concentrations in
children with obesity distinctly correlate with sVCAM-1
and sE-selectin [14].
To further dissect potential mechanisms of increased
CAMs serum concentrations, we compared age-, sex-,
BMI-, and body fat mass- matched MHO categories of
insulin sensitivity and insulin resistance as previously
described [6]. Significantly higher ICAM-1, E-selectin, and
P-selectin serum concentrations in IR compared to IS MHO
suggest that insulin resistance, but also other factors dis-
criminating these two groups such as higher visceral fat
mass, adipose tissue inflammation, and alterations in the
adipokine secretion pattern play a role in the regulation of
CAMs serum concentrations. These data add to our pre-
vious findings that hyperinsulinemia and chronic hyper-
glycemia are related to higher circulating CAMs [10].
There was no subgroup imbalance with regard to the
number of individuals with IFG suggesting that those
people with IFG-related increased risk for diabetes may not
have introduced a bias to the observed group differences in
circulating adhesion molecules.
Noteworthy, visceral (but not subcutaneous) adipose
tissue has been previously identified as a major source of
increased CAMs serum concentrations [11] and may further
contribute to the highest circulating CAMs found in the
MUO subgroup. In addition, it has been previously shown
that monocyte expression of CD11b, one of the counter
receptors for CAMs, may be upregulated in patients with
obesity depending on adipose tissue immune cell infiltration
[15]. Together with our observation that macrophage infil-
tration into visceral adipose tissue discriminates between IS
and IR MHO [6], these data [15] suggest that a low-grade
inflammatory response in adipose tissue may link impaired
adipose tissue function to both higher circulating CAMs and
monocyte CD11b expression.
Taken together, our data suggest that adipose tissue
accumulation may be independently of major cardio-
metabolic risk factors related to elevated circulating
CAMs. Higher sCAMs in people with IR compared to IS
MHO further point to additional mechanistic links between
adipose tissue dysfunction, systemic insulin resistance, and
the potentially atherogenic risk profile even beyond effects
of increased fat mass.
Future longitudinal studies are required to test the
hypothesis that vascular inflammation related to obesity and
impaired adipose tissue function could be early predicted by
circulating sCAMs. In addition, the effects of anti-
inflammatory pharmacotherapies or behavior interventions
on circulating CAMs should be investigated in future trials.
Data from our human model system may stimulate studies
aiming at identifying the molecular mechanisms underlying
the observed associations.
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